TLK2 and neoplasm: In particular, GOBO-based analysis [50] indicates that TLK2 is overexpressed in 37 % luminal (estrogen receptor (ER)-positive) breast tumours, and grade 3-stratified multivariate analysis indicates a hazard ratio of 2.25 (p = 10−5) and poor survival (p < 0.01) in patients with these tumours (Additional file 1).